VIDAZA Drug Use Examination
Phase of Trial: Phase IV
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 24 Aug 2016 Status changed from active, no longer recruiting to completed.
- 15 Jan 2016 Planned End Date changed from 1 Nov 2016 to 1 May 2016 according to ClinicalTrials.gov.
- 15 Jan 2016 Planned primary completion date changed from 1 Aug 2016 to 1 May 2016 according to ClinicalTrials.gov.